New drug combo shows promise for rare blood cancers
NCT ID NCT04493138
First seen Nov 01, 2025 · Last updated Jun 08, 2026 · Updated 37 times
Summary
This study tests a combination of two drugs, azacitidine and quizartinib, in 30 adults with myelodysplastic syndromes or related blood cancers that have specific gene changes (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the disease. Participants must have certain risk levels or high-risk features.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.